Meher Angez, Rabeet Tariq, Alveena Zafar, Ali Azan Ahmed, Ayesha Nasir Hameed, Usama Waqar, Syed Ather Enam
{"title":"Second Primary Tumors After Primary Brain Tumors and Vice Versa: A Single-Center, Retrospective Study.","authors":"Meher Angez, Rabeet Tariq, Alveena Zafar, Ali Azan Ahmed, Ayesha Nasir Hameed, Usama Waqar, Syed Ather Enam","doi":"10.14791/btrt.2024.0041","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Advancements in surgery, chemotherapy, and radiotherapy have improved survival for brain tumor patients, increasing the risk of second primary tumors (SPTs) among long-term survivors. This study examines the types and risks of SPTs in brain tumor patients presenting at a tertiary care hospital.</p><p><strong>Methods: </strong>This single-center, retrospective study explored occurrences of SPTs following primary brain tumors and occurrences of brain tumors as SPTs following primary extra neural tumors. A total of 41 patients were included and analyzed presenting with histologically confirmed SPTs between 1st January 2000 and 31st December 2020.</p><p><strong>Results: </strong>The study included 41 patients with SPTs, primarily female (65.9%). Of these, 20 patients (48.7%) developed SPTs after a primary brain tumor, while 21 patients (51.2%) developed brain tumors as SPTs after extra-neural tumors. Among patients who developed SPTs after brain tumors (n=20), meningioma (n=8, 40.0%) and pituitary adenoma (n=6, 30.0%) were the most prevalent first primary tumors (FPTs) while breast tumors predominated as SPTs (n=4, 20.0%). Survival analysis indicated younger mean age (44.5 years) for patients marked alive, compared to those marked deceased (57.0 years) and those with unknown outcomes (63.0 years).</p><p><strong>Conclusion: </strong>Based on this retrospective analysis, the median age at diagnosis was 44.5 years, with a considerable number of patients (36.6%) having uncertain outcomes at follow-up due to incomplete records. These findings highlight the need for improved follow-up data management to better assess long-term survival in patients with SPTs following brain tumors.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 1","pages":"17-22"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813562/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain tumor research and treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14791/btrt.2024.0041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Advancements in surgery, chemotherapy, and radiotherapy have improved survival for brain tumor patients, increasing the risk of second primary tumors (SPTs) among long-term survivors. This study examines the types and risks of SPTs in brain tumor patients presenting at a tertiary care hospital.
Methods: This single-center, retrospective study explored occurrences of SPTs following primary brain tumors and occurrences of brain tumors as SPTs following primary extra neural tumors. A total of 41 patients were included and analyzed presenting with histologically confirmed SPTs between 1st January 2000 and 31st December 2020.
Results: The study included 41 patients with SPTs, primarily female (65.9%). Of these, 20 patients (48.7%) developed SPTs after a primary brain tumor, while 21 patients (51.2%) developed brain tumors as SPTs after extra-neural tumors. Among patients who developed SPTs after brain tumors (n=20), meningioma (n=8, 40.0%) and pituitary adenoma (n=6, 30.0%) were the most prevalent first primary tumors (FPTs) while breast tumors predominated as SPTs (n=4, 20.0%). Survival analysis indicated younger mean age (44.5 years) for patients marked alive, compared to those marked deceased (57.0 years) and those with unknown outcomes (63.0 years).
Conclusion: Based on this retrospective analysis, the median age at diagnosis was 44.5 years, with a considerable number of patients (36.6%) having uncertain outcomes at follow-up due to incomplete records. These findings highlight the need for improved follow-up data management to better assess long-term survival in patients with SPTs following brain tumors.